A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS)

Tuğcu, Volkan; Taşçı, Ali İhsan; Fazlıoğlu, Adem; Gürbüz, Gökhan; Özbek, Emin; Sahin, Şevki; Kurtuluş, Fatih; Çek, Mete

doi:10.1016/j.eururo.2006.09.036

Cited by 83 publications

(75 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most (eight) showed positive results, with significant differences vs placebo in NIH-CPSI total, urinary symptom, pain, and/or QoL scores [54][55][56][57]59,60], or in scores using other validated symptom scoring tools [58,61]. However, there was heterogeneity in primary endpoints, patient eligibility criteria (e.g.…”

Section: A-adrenergic Antagonistsmentioning

confidence: 99%

“…In all, 10 placebo-controlled RCTs (n = 58-272) were identified that evaluated a-adrenergic antagonists (tamsulosin [53][54][55], alfuzosin [56,57], doxazosin [58,59], terazosin [60,61] and silodosin [62]) in CBP and CP/CPPS. Most (eight) showed positive results, with significant differences vs placebo in NIH-CPSI total, urinary symptom, pain, and/or QoL scores [54][55][56][57]59,60], or in scores using other validated symptom scoring tools [58,61].…”

Section: A-adrenergic Antagonistsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Rees

Abrahams

Doble³

et al. 2015

BJU International

246

193

View full text Add to dashboard Cite

ObjectivesTo improve awareness and recognition of chronic bacterial prostatitis (CBP) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) among non-specialists and patients. To provide guidance to healthcare professionals treating patients with CBP and CP/CPPS, in both non-specialist and specialist settings. To promote efficient referral of care between nonspecialists and specialists and the involvement of the multidisciplinary team (MDT). Patients and MethodsThe guideline population were men with CBP or CP/CPPS (persistent or recurrent symptoms and no other urogenital pathology for ≥3 of the previous 6 months). Consensus recommendations for the guidelines were based on a search to identify literature on the diagnosis and management of CBP and CP/CPPS (published between 1999 and February 2014). A Delphi panel process was used where high-quality, published evidence was lacking. ResultsCBP and CP/CPPS can present with a wide range of clinical manifestations. The four main symptom domains are urogenital pain, lower urinary tract symptoms (LUTSvoiding or storage symptoms), psychological issues and sexual dysfunction. Patients should be managed according to their individual symptom pattern. Options for first-line treatment include antibiotics, a-adrenergic antagonists (if voiding LUTS are present) and simple analgesics. Repeated use of antibiotics, such as quinolones, should be avoided if there is no obvious symptomatic benefit from infection control or cultures do not support an infectious cause. Early use of treatments targeting neuropathic pain and/or referral to specialist services should be considered for patients who do not respond to initial measures. An MDT approach (urologists, pain specialists, nurse specialists, specialist physiotherapists, general practitioners, cognitive behavioural therapists/psychologists, and sexual health specialists) is recommended. Patients should be fully informed about the possible underlying causes and treatment options, including an explanation of the chronic pain cycle. ConclusionChronic prostatitis can present with a wide variety of signs and symptoms. Identification of individual symptom patterns and a symptom-based treatment approach are recommended. Further research is required to evaluate management options for CBP and CP/CPPS.

show abstract

Section: A-adrenergic Antagonistsmentioning

confidence: 99%

Section: A-adrenergic Antagonistsmentioning

confidence: 99%

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Rees

Abrahams

Doble³

et al. 2015

BJU International

246

193

View full text Add to dashboard Cite

show abstract

“…Antibiotics administration is the standard treatment for chronic bacterial prostatitis [19], however, the standard treatment for CP/CPPS has not yet been established [20]. To date, various treatments for CP/CPPS have been reported, including α-blockers, antibiotics, anti-inflammatory agents, phytotherapeutics, and various other modalities [4][5][6][7][8][9][10][11][12].…”

Section: Discussionmentioning

confidence: 99%

567 Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study

Imai¹,

Yoneyama²,

Hashimoto³

et al. 2014

European Urology Supplements

View full text Add to dashboard Cite

“…Recently, a combination treatment for CP/CPPS has been suggested as a preferred method due to its synergistic effect, showing superiority over monotherapy [14,15]. Combination therapy was based on the UPOINT system of domains (urinary, psychosocial, organ-specific, infection, neurologic/systemic, and tenderness) [16].…”

Section: Discussionmentioning

confidence: 99%

The Effects of Microwave Thermotherapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective, Randomized Study

Chung

Choi

Yoo

et al. 2017

Urogenit Tract Infect

View full text Add to dashboard Cite

Purpose: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) causes pain and urinary symptoms that involve the prostate and/or other parts of the male. We analyzed the clinical outcomes of medication and microwave thermotherapy. Materials and Methods: A total of 132 patients with CP/CPPS for at least 3 months were assigned to one of the three study groups (group A: medication; group B: thermotherapy; group C: combination therapy). The NIH-CPSI was recorded at baseline, and at weeks 2, 4, 8, and 12 post-therapy. EPS was evaluated, and semen analysis was performed to assess the changes in prostatic inflammation. Moreover, patient satisfaction questionnaire was completed. Results:Comparisons between groups A and B, as well as between groups B and C showed no significant changes in pain, quality of life, and total scores. At week 12, group C, when compared with group A, had a significantly improved voiding score (4.19±3.02 vs. 2.71±2.30, p=0.019) and EPS (12.47±15.91 vs. 3.73±4.82, p=0.003). At week 4, the patient satisfaction score in group C was significantly different from that in other groups (p=0.043), but there was no difference at week 12 (p＞0.05). There was no statistically significant difference in laboratory test results, PSA, and prostate volume between the three groups at baseline and week 12. Complications of thermotherapy resolved with conservative management. Conclusions: Our results showed that a combination of medication and thermotherapy improved NIH-CPSI and patient satisfaction in CP/CPPS more than medication alone. We suggested that thermotherapy could be another treatment option for CP/CPPS.

show abstract

A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS)

Cited by 83 publications

References 21 publications

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

567 Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study

The Effects of Microwave Thermotherapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective, Randomized Study

Contact Info

Product

Resources

About